High-dose tamoxifen added to concurrent biochemotherapy with decrescendo interleukin-2 in patients with metastatic melanoma

Cancer

Volumn 92, Issue 3, 2001, Pages 609-619

  O'Day, Steven J ^a,b   Boasberg, Peter D ^a,b   Kristedja, Tim S ^a,b   Martin, Maureen ^a,b   Wang, He Jing ^a,b   Fournier, Patricia ^a,b   Cabot, Myles ^a,b   Degregorio, Michael W ^a,b   Gammon, Guy ^a,b  

^a JOHN WAYNE CANCER INSTITUTE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Biochemotherapy; Decrescendo interleukin 2; Metastatic melanoma; Tamoxifen

Indexed keywords

ALPHA2B INTERFERON; CISPLATIN; DACARBAZINE; INTERLEUKIN 2; TAMOXIFEN; VINBLASTINE;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HUMAN; MALE; MELANOMA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC AGENTS, HORMONAL; FEMALE; HUMANS; INTERLEUKIN-2; MALE; MELANOMA; MIDDLE AGED; SURVIVAL RATE; TAMOXIFEN; TREATMENT OUTCOME;

EID: 0035425456     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/1097-0142(20010801)92:3<609::AID-CNCR1361>3.0.CO;2-U     Document Type: Article

References (58)

1. The incidence of malignant melanoma in the United States: Issues as we approach the 21st century
2. A multifactorial analysis of melanoma. IV. Prognostic factors in 200 melanoma patients with distant metastases (stage III)
3. Cutaneous melanoma: Prognosis and treatment results worldwide
4. Prognostic factors in 1,521 melanoma patients with distant metastases
5. Chemotherapy for malignant melanoma: Combinations and high doses produce more responses without survival benefit
6. Dimethyl triazeno imidazole carboxamide and combination therapy for melanoma. IV. Late results after complete response to chemotherapy (Central Oncology Group protocols 7130, 7131, and 7131A)
7. Current therapy for malignant melanoma
8. A prospective evaluation of a triple-drug regimen containing cisplatin, vinblastine, and dacarbazine (CVD) for metastatic melanoma
9. Complete responses and long-term survivals after systemic chemotherapy for patients with advanced malignant melanoma
10. The role of interferon alfa in the treatment of metastatic melanoma
11. Studies of interferons in the therapy of melanoma
12. Recombinant interferons in the management of advanced malignant melanoma. Updated review of five prospective clinical trials and long-term responders
13. Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin 2
14. High dose IL-2 therapy alone results in long-term durable complete responses in patients with metastatic melanoma
15. Sequential chemoimmunotherapy in the treatment of metastatic melanoma
16. Sequential chemoimmunotherapy with cisplatin, interleukin-2, and interferon alfa-2a for metastatic melanoma
17. A phase II study of dacarbazine and cisplatin in combination with outpatient administered interleukin-2 in metastatic malignant melanoma
18. Development and results of biochemotherapy in metastatic melanoma: The University of Texas M.D. Anderson Cancer Center experience
19. Treatment of metastatic melanoma with combined chemotherapy containing cisplatin, vinblastine and dacarbazine (CVD) and biotherapy using interleukin-2 and interferon-alpha
20. Salpetriere Hospital experience with biochemotherapy in metastatic melanoma
21. Multi-institutional phase II trial of intensive combination chemoimmunotherapy for metastatic melanoma
22. Combination of chemotherapy with interleukin-2 and interferon-alfa for the treatment of advanced melanoma
23. Phase II study of neoadjuvant concurrent biochemotherapy in melanoma patients with local-regional metastases
24. Combination of chemotherapy with interleukin-2 and interferon alfa for the treatment of metastatic melanoma
25. Durable complete responses in metastatic melanoma treated with interleukin-2 in combination with interferon alpha and chemotherapy
26. Development of a biochemotherapy regimen with concurrent administration of cisplatin, vinblastine, dacarbazine, interferon alfa, and interleukin-2 for patients with metastatic melanoma
27. Results of interleukin-2-based treatment in advanced melanoma: A case record-based analysis of 631 patients
28. Interferon alfa-2a and interleukin-2 with or without cisplatin in metastatic melanoma: A randomized trial of the European Organization for Research and Treatment of Cancer Melanoma Cooperative Group
29. Interferon-alpha and interleukin-2 in the treatment of metastatic melanoma. Comparison of two phase II trials
30. Phase III randomized trial of cisplatin, vinblastine and dacarbazine (CVD) plus interleukin-2 (IL2) and interferon-alpha-2b (INF) versus CVD in patients (Pts) with metastatic melanoma
31. Effect of tamoxifen on mitoxantrone cytotoxicity in drug-sensitive and multidrug-resistant MCF-7 cells
32. Reversal of P-glycoprotein-mediated multidrug resistance by pure anti-oestrogens and novel tamoxifen derivatives
33. Modulation of cisplatin resistance in human malignant melanoma cells
34. Tamoxifen modulation of cisplatin sensitivity in human malignant melanoma cells
35. Agents that reverse multidrug resistance, tamoxifen, verapamil, and cyclosporin A, block glycosphingolipid metabolism by inhibiting ceramide glycosylation in human cancer cells
36. Tamoxifen retards glycosphingolipid metabolism in human cancer cells
37. Synergistic antitumor effects of a combination of interferon and tamoxifen on estrogen receptor-positive and receptor-negative human tumor cell lines in vivo and in vitro
38. Effective combination chemo/hormonal therapy for malignant melanoma: Experience with three consecutive trials
39. The importance of tamoxifen to a cisplatin-containing regimen in the treatment of metastatic melanoma
40. Combination chemotherapy and hormonal therapy in the treatment of malignant melanoma
41. Randomized, double-blind, placebo-controlled trial comparing the response rates of carmustine, dacarbazine, and cisplatin with and without tamoxifen in patients with metastatic melanoma
42. Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in with metastatic melanoma
43. A phase II study of tamoxifen combined with cisplatin-interleukin 2 and alpha-interferon in metastatic melanoma
44. Advantages of concurrent biochemotherapy modified by decrescendo interleukin-2, granulocyte colony-stimulating factor, and tamoxifen for patients with metastatic melanoma
45. High-dose tamoxifen as an enhancer of etoposide cytotoxicity. Clinical effects and in vitro assessment in p-glycoprotein expressing cell lines
46. Intermittent high-dose tamoxifen as a potential modifier of multidrug resistance
47. Clinical pharmacology of tamoxifen in patients with breast cancer: Comparison of traditional and loading dose schedules
48. Quantitation of tamoxifen, 4-hydroxytamoxifen, and N-desmethyltamoxifen in human plasma by high-performance liquid chromatography
49. Reducing bias in observational studies using subclassification on the propensity score
50. The analysis of several 2 × 2 contingency tables
51. Distribution of 4-hydroxy-N-desmethyltamoxifen and other tamoxifen metabolites in human biological fluids during tamoxifen treatment
52. Pharmacokinetics of anti-endocrine agents
53. Targeting chemosensitizing doses of toremifene based on protein binding
54. Tamoxifen activates cellular phospholipase C and D and elicits protein kinase C translocation
55. Recent advances in understanding the molecular mechanisms of tamoxifen action
56. Tamoxifen induces selective membrane association of protein kinase C epsilon in MCF-7 human breast cancer cells